<DOC>
	<DOCNO>NCT00775359</DOCNO>
	<brief_summary>The objective study compare single-dose relative bioavailability Ranbaxy Abbott ( TriCor ) 160 mg fenofibrate tablet feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Fenofibrate 160mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>This open-label , randomize , single-dose , 2-way crossover , relative bioavailability study perform 24 healthy adult male female volunteer A total 23 subject ( 16 male 7 female ) complete clinical phase study . In period , subject house even dose 24-hour blood draw . Subjects return subsequent blood draw . Doses separate washout period 10 day . Of 24 healthy adult male female volunteer enrol study , 23 subject ( 16 male 7 female ) complete clinical phase study . Subject No . 10 fail return Period 2 check-in .</detailed_description>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Subject candidate must fulfill follow inclusion criterion eligible participation study , unless otherwise specify : Healthy adult male female volunteer , 1855 year age ; Weighing least 52 kg male 45 kg female within 15 % ideal weight ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) ; Medically healthy subject clinically abnormal laboratory ECGs , deem principal investigator ; Females childbearing potential either sexually inactive ( abstinent ) 14 day prior study throughout study use one follow acceptable birth control method : Surgically sterile ( tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum . Proof required hysterectomy oophorectomy ; IUD place least 3 month ; Barrier method spermicide ( condom , diaphragm ) least 14 day prior start study throughout study ; Surgical sterilization partner ( vasectomy 6 month minimum ) ; Hormonal contraceptive least 3 month prior start study . Other birth control method may deem acceptable . Postmenopausal woman amenorrhea least 2 year ; Voluntary consent participate study . Subject candidate must enrol study meet follow criterion : History presence significant : cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic psychiatric disease . In addition , history presence : alcoholism drug abuse within past 2 year ; hypersensitivity idiosyncratic reaction fenofibrate lipid regulating agent . Female subject pregnant lactating . Subjects abnormal diet ( whatever reason ) 30 day prior first dose . Subjects make donation ( standard donation amount ) blood blood product ( exception plasma note ) within 30 day prior study . Subjects make plasma donation within 7 day prior study . Subjects participate another clinical trial within 30 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>bioequivalence fenofibrate tablet</keyword>
</DOC>